key: cord-0908737-6ptaxg74
authors: Titanji, Boghuma K; Farley, Monica M; Schinazi, Raymond F; Marconi, Vincent C
title: Response to Correspondence: Baricitinib – Impact on COVID-19 Coagulopathy? Jorgensen et. al.
date: 2020-08-14
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1210
sha: b357c6f6a1c161181af284812c4bbbd5543e69c6
doc_id: 908737
cord_uid: 6ptaxg74

nan

A c c e p t e d M a n u s c r i p t This does not, however, preclude the possibility of an imbalance between arms that could emerge during the final trial analysis. Baricitinib through its immunomodulatory effects as highlighted by Jorgensen et.al may in fact be beneficial in terms of reducing coagulopathy in patients with COVID-19, which is thought to be primarily mediated by hyper-inflammation and endothelial damage. All of the cohort studies of baricitinib for COVID-19 treatment led to significant decline in inflammatory M a n u s c r i p t markers for patients who received the drug 2,3,8 . We agree that in the pursuit of effective therapeutics against COVID-19, there is a need to balance the potential adverse effects of any intervention with its hypothesized benefits and to perform randomized, controlled trials. Regarding baricitinib, ACTT2 should provide clarity on the VTE issue in the near future and its role in the treatment of COVID-19 in moderate to severe patients.

A c c e p t e d M a n u s c r i p t

Thromboembolic safety reporting of Tofacitinib and Baricitinib: an analysis of the WHO VigiBase. Drug Saf

Baricitinib restrains the immune dysregulation in COVID-19 patients. medRxiv20135319

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Combination of Ruxolitinib and Eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients

Use of Baricitinib in patients with moderate and severe COVID-19

FRI0123 Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis

Cardiovascular safety during treatment with Baricitinib in rheumatoid arthritis

Vincent Marconi and Raymond F Schinazi are partially funded by -Emory University Center for AIDS Research (AI050409). Raymond F Schinazi is funded in part by NIH grant 5-R01-MH116695.

Dr. Vincent C. Marconi has consulted or received research support from ViiV, Gilead, Lilly and Bayer. Dr. Raymond Schinazi served as an unpaid consultant for Eli Lilly whose drugs are being evaluated in the research described in this paper. In addition, Dr. Schinazi owns shares in Eli Lilly and Gilead, and is issued patents 20190134039, 10022378, and 9662332. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies. All other authors do not have any conflicts to declare.

A c c e p t e d M a n u s c r i p t